Effects of dapagliflozin in DAPA-HF according to background heart failure therapy

AIMS: In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined whether this benefit was consistent in relation to background HF therapy. METHODS AND RESULTS: In this post hoc anal...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Heart J
Main Authors: Docherty, Kieran F, Jhund, Pardeep S, Inzucchi, Silvio E, Køber, Lars, Kosiborod, Mikhail N, Martinez, Felipe A, Ponikowski, Piotr, DeMets, David L, Sabatine, Marc S, Bengtsson, Olof, Sjöstrand, Mikaela, Langkilde, Anna Maria, Desai, Akshay S, Diez, Mirta, Howlett, Jonathan G, Katova, Tzvetana, Ljungman, Charlotta E A, O’Meara, Eileen, Petrie, Mark C, Schou, Morten, Verma, Subodh, Vinh, Pham Nguyen, Solomon, Scott D, McMurray, John J V
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Fast Track Clinical Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7327533/
https://ncbi.nlm.nih.gov/pubmed/32221582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehaa183
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados